DAYTON — Miami Valley Hospital has been chosen as a site for clinical trials of an experimental antibody treatment that was one of the treatments used on President Donald Trump.
The hospital is enrolling patients in the Regeneron investigational COVID-19 antibody treatment for patients who have been diagnosed with the virus and are either hospitalized or are recovering at home, a hospital spokesperson said in a media release Monday.
The treatment, named REGN-COV2, is described as an antibody cocktail that is still in clinical trials for treatment of COVID-19.
“It consists of two potent, complementary virus-neutralizing antibodies and was designed specifically to target the SARS-CoV-2 (COVID-19) virus,” the spokesperson said. “Preliminary data released by Regeneron showed that REGN-COV2 reduced viral levels and time to alleviate symptoms in non-hospitalized patients with COVID-19.”
Trump was a recipient of a dose of REGN-COV2 during his treatment of COVID-19, following a request from his physicians, the spokesperson added.
Those wishing to be a part of the clinical trial are asked to complete a brief screening survey, found here, to see if they qualify.